Efficacy results for ONC201 in recurrent glioblastoma published

Washington University in St. Louis receives $2M from CureSearch for pediatric brain cancer phase I study

CureSearch for Children’s Cancer will award $2 million in funding to support a phase I clinical trial in 24 children and young adults with recurrent brain tumors.

September 06, 2024

Vol.50 No.33

Funding Opportunities

DOD Glioblastoma Research Program anticipated funding opportunities for FY24

The FY24 Defense Appropriations Act provides funding for the Glioblastoma Research Program to support high impact research to reduce the burden of glioblastoma on service members and their families, veterans, and the American public.

September 06, 2024

Vol.50 No.33

In Brief

NeOnc Technologies receives California Investment Forum’s Breakthrough Medical Technology Achievement Award

NeOnc Technologies Holdings Inc., a clinical-stage biopharmaceutical company, has received the Breakthrough Medical Technology Achievement Award from the California Investment Forum for its innovations in medical technology related to the treatment of brain and central nervous system diseases.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Serotonin-producing neurons regulate malignancy in ependymoma brain tumors

A study published in Nature reveals the functional relevance of tumor-neuron interactions that regulate the growth of ependymoma brain tumors.

August 02, 2024

Vol.50 No.31

Clinical Roundup

AI system identifies genes that can convert brain cancer cells into functioning immune cells in mice

In an innovative new study of glioblastoma, scientists used artificial intelligence to reprogram cancer cells, converting them into dendritic cells, which can identify cancer cells and direct other immune cells to kill them.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Unexpected role of OTX2 drives aggressive medulloblastoma

Researchers at Baylor College of Medicine, Texas Children’s Hospital, the University of Manitoba, and collaborating institutions revealed an unexpected way in which the protein OTX2 drives the progression of medulloblastoma—the most common aggressive childhood brain cancer.

July 19, 2024

Vol.50 No.29

Efficacy results for ONC201 in recurrent glioblastoma published

YOU MAY BE INTERESTED IN

Washington University in St. Louis receives $2M from CureSearch for pediatric brain cancer phase I study

DOD Glioblastoma Research Program anticipated funding opportunities for FY24

NeOnc Technologies receives California Investment Forum’s Breakthrough Medical Technology Achievement Award

Serotonin-producing neurons regulate malignancy in ependymoma brain tumors

AI system identifies genes that can convert brain cancer cells into functioning immune cells in mice

Unexpected role of OTX2 drives aggressive medulloblastoma

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login